← Azimuth Daily
Capturing data…
Capturing data…
MON, 28 SEPT · 76 ITEMS
"Glucosamine use linked to 25% higher likelihood of progression from mild cognitive impairment to dementia" — Science Daily (all) · Science & Medicine
This reports an observational study, likely from the University of Florida, showing that people with mild cognitive impairment (MCI) who take —a common joint supplement—were 25% more likely to progress to dementia (likely Alzheimer's disease) over five years, compared with non-users. The study used electronic health records and controlled for basic demographics, but it does not prove causation. The same research also published a mechanistic paper in *Nature Metabolism* proposing that glucosamine may drive Alzheimer's by promoting , a metabolic process that could accelerate neurodegeneration.
The claim comes from a peer-reviewed study published in *Nature Metabolism* (June 2026) and was covered by multiple reputable outlets (Science Daily, UF Health, The Conversation), all reporting the same 25% figure. The study design is observational (electronic health record analysis), so residual confounding is possible; however, the large sample size and consistent reporting across sources give the association reasonable solidity. The reporting sits close to the primary source, with several articles directly linking to or summarizing the paper.
Genuinely new as of late September 2026, based on the Science Daily release date of September 27, 2026, and the surrounding study publication in June 2026; this is not a recirculation of older material.
Past coverage from June 2026 noted the initial publication of this same UF study in *Nature Metabolism*, reporting the 25% increased risk and the hyperglycosylation mechanism—this September item is a later wave of the same story.